Pharming Gets FDA Approval for Joenja to Treat APDS in Children Aged 4-11
MT Newswires Live
10 hours ago
Pharming's (PHAR) Joenja tablets have been approved to treat activated phosphoinositide 3-kinase delta syndrome, or APDS, in children 4-11 years who weigh at least 27 kg, the US Food and Drug Administration said Friday.
Joenja was first approved in 2023 for the same indication in patients 12 years and older, the regulator said. APDS is a rare genetic disorder that impairs cells of the immune system.
Shares were about 1.6% higher in afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.